# Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers

> **NCT02387242** · PHASE1 · SUSPENDED · sponsor: **National University Hospital, Singapore** · enrollment: 18 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT02387242
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2015-02
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 18 (ESTIMATED)
- **Why stopped:** New relevant data published
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387242, "Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02387242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*